I doubt the company would be offereing a 1:1 dividend if they thought the eventual share price would land at 60 cents or so. They must think that once it is on the Nasdaq the price will naturally rise quite a bit as institutional investors climb on board. Also, they may have more news that would spur buying.
Interesting the news release seemed to imply that the Nasdaq uplisting was not a question of GNBT qualifying, but just a question of completing paperwork. I know it didn't say this explicity, but it was my take-a-way sense of it.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links